What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care
NCT04794816
Recruiting
This study explores why patients may want to receive real-time imaging results during a screening mammogram appointment at an MD Anderson breast imaging center. Real-time imaging results means women receive the results of the mammogram right away during the same clinic visit. Information from this study may help researchers better understand patient preferences to enhance patient-experience driven care.
Gender:
FEMALE
Ages:
30 years and above
Trial Updated:
04/24/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Carcinoma
Register for Updates
Combination Therapy for the Treatment of Diffuse Midline Gliomas
NCT05009992
Recruiting
This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. ONC201, panobinostat, and paxalisib are all enzyme inhibitors that may stop the growth of tumor cells by clocking some of the enzymes needed for cell growth. This phas... Read More
Gender:
ALL
Ages:
Between 2 years and 39 years
Trial Updated:
04/24/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +31 locations
Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Register for Updates
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283
Recruiting
This is a study evaluating the safety, pharmacokinetics, and efficacy of MK-1084 alone, and MK-1084 plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Moffitt Cancer Center ( Site 0261), Tampa, Florida +67 locations
Conditions: Advanced Solid Tumors
Register for Updates
Stimulation of the Larynx to Treat Unexplained Chronic Cough
NCT05273190
Recruiting
Researchers will test the effect of non-invasive vibrotactile stimulation of the larynx on symptom severity of unexplained chronic cough.
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
04/24/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Cough
Register for Updates
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT05424822
Recruiting
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: City of Hope, Duarte, California +28 locations
Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Register for Updates
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
NCT05561114
Recruiting
To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
04/24/2025
Locations: Birmingham Gastroenterology Associates, Birmingham, Alabama +34 locations
Conditions: Esophageal Stricture
Register for Updates
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
NCT05743517
Recruiting
The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core intervention of a wearable activity tracker and commercially available app, will improve physical activity. The findings will generate meaningful knowledge about how to best increase physical activity in older gynecologic cancer patients receiving systemic cancer therapies to improve quality of life and cancer-specific s... Read More
Gender:
FEMALE
Ages:
60 years and above
Trial Updated:
04/24/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Ovary Cancer, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Cervix Cancer, Vulvar Cancer, Vaginal Cancer
Register for Updates
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
NCT05832229
Recruiting
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2025
Locations: University of California San Diego NAFLD Research Center, La Jolla, California +12 locations
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Register for Updates
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530
Recruiting
The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab given alone as further therapy in participants with resectable and borderline resectable stage IIB-IIIB NSCLC.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/24/2025
Locations: Research Site, Duarte, California +69 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
NCT06014658
Recruiting
This is a first-in-human (FIH), open label Phase 1/1b / Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-101 at potential OBRDs. Phase 1 and Phase 1b will both characterize single and multiple-dose PK profiles and eva... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +16 locations
Conditions: Cancer
Register for Updates
Mother-Baby Study - Caloric Compensation Index (COMPX)
NCT06072664
Recruiting
The study will test a model of biobehavioral mechanisms involved in the development of a system of emotion, attachment, and nutritive intake in the mother-infant dyad and the association of this system with maternal feeding behavior, child eating behavior, dietary intake, and adiposity. To participate in this study the infant must also be enrolled in long-term observational study, NCT06039878.
Gender:
ALL
Ages:
0 days and above
Trial Updated:
04/24/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Eating Behavior
Register for Updates
Black Women's Life Experience On Cardiovascular Health Via Ongoing Monitoring
NCT06150989
Recruiting
This pilot study uses a state-of-the-science combination of remote behavioral monitoring, real-time experience sampling, in-lab physiological assessments, and extraction of neighborhood-level characteristics to (1) Examine the impact of daily experience (i.e., racial discrimination, affective states, stress) on health behaviors (i.e., physical activity, sedentary behavior, sleep) at the intrapersonal level among Black women; (2) Test the association between daily behaviors and impairments in bio... Read More
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
04/24/2025
Locations: The University of Texas at Arlington, Arlington, Texas
Conditions: Cardiovascular Diseases, Heart Disease Risk Factors
Register for Updates